Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Felix B who wrote (2475)	8/15/2018 7:18:37 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 3559

It was not pre-specified analysis (it was per protocol, from start, second year, flexible dosing,..), so whatever they want to put in label (fixed wording)...it will be in arguing mode! I do believe that they will have positive vote (with less strong label for 12 w dosing). CMC medicare Advantage damage is more as FEAR then real...but it is there and will not be resolved quickly. Stock price is effected, nonetheless.